Submit Deal

AEGLEA BIOTHERAPEUTICS

Summary

Aeglea is a biotechnology company focused on advancing a robust pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 87 M

Avg. Deal Size£ 87 M

Market Context

Senior Management

Jonathan Alspaugh
President and CFO

Sort

22 Jun 2023|United States|Biotechnology

Target: SPYRE THERAPEUTICS

Bidder: AEGLEA BIOTHERAPEUTICS

9 Service Providers

5 Target | 4 Bidder

17 Dealmakers

1 Target | 16 Bidder

£ 86 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy